端粒缩短与骨髓衰竭性疾病的研究进展

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (1): 116-119.

端粒缩短与骨髓衰竭性疾病的研究进展

高小燕, 刘述川^*

哈尔滨医科大学附属第一医院血液内科, 黑龙江哈尔滨 150001

收稿日期:2019-10-24 修回日期:2020-01-27 出版日期:2021-01-05 发布日期:2020-12-30
通讯作者: ^*lsc1972@163.com
基金资助:
黑龙江省教育厅科研基金(11541227)

Research advance on telomere shortening and bone marrow failure diseases

GAO Xiao-yan, LIU Shu-chuan^*

Department of Hematology, the First Affiliated Hospital of Harbin Medical University, Harbin 150001, China

Received:2019-10-24 Revised:2020-01-27 Online:2021-01-05 Published:2020-12-30
Contact: ^*lsc1972@163.com

摘要/Abstract

摘要： 端粒缩短是骨髓衰竭性疾病的重要发病机制,以端粒为诊疗靶点可能成为骨髓衰竭性疾病的研究新方向。端粒缩短与临床常见的获得性骨髓衰竭性疾病,包括再生障碍性贫血、骨髓增生异常综合征和免疫相关性全血细胞减少症,以及部分先天性骨髓衰竭性疾病,包括先天性角化不良和范科尼贫血有关。

关键词: 端粒缩短, 基因突变, 骨髓衰竭性疾病, 再生障碍性贫血, 骨髓增生异常综合征

Abstract: Telomere shortening is an important pathogenesis of bone marrow failure diseases. As a therapeutic target, telomere may become a new research direction for bone marrow failure diseases. Telomere shortening is related to clinical acquired bone marrow failure diseases, including aplastic anemia, myelodysplastic syndrome and immune mechanism related pancytopenia. The relation between telomere shortening and some inherited bone marrow failure diseases, including dyskeratosis congenita, fanconi anemia is also referred.

Key words: telomere shortening, genetic mutations, bone marrow failure diseases, aplastic anemia, myelodysplastic syndrome

中图分类号:

R551.3

高小燕, 刘述川. 端粒缩短与骨髓衰竭性疾病的研究进展[J]. 基础医学与临床, 2021, 41(1): 116-119.

GAO Xiao-yan, LIU Shu-chuan. Research advance on telomere shortening and bone marrow failure diseases[J]. Basic & Clinical Medicine, 2021, 41(1): 116-119.

参考文献

[1] Shay JW. Telomeres and aging[J]. Curr Opin Cell Biol, 2018, 52: 1-7.
[2] Martinez P, Blasco MA. Telomere-driven diseases and telomere-targeting therapies[J]. J Cell Biol, 2017, 216: 875-887.
[3] Allegra A, Innao V, Penna G, et al. Telomerase and telomere biology in hematological diseases: A new therapeutic target[J]. Leukemia Res, 2017, 56: 60-74.
[4] Maciejowski J, Lange TD. Telomeres in cancer: tumour suppression and genome instability[J]. Nat Rev Mol Cell Bio, 2017, 18: 175-186.
[5] Roake CM, Artandi SE. Control of cellular aging, tissue function, and cancer by p53 downstream of telomeres[J]. CSH Perspect Med,2017,7.doi:10.1101/cshperspect.a026088.
[6] Hrgovic I, Doll M, Kleemann J, et al. The histone deacetylase inhibitor trichostatin a decreases lymphangiogenesis by inducing apoptosis and cell cycle arrest via p21-dependent pathways[J]. BMC cancer, 2016, 16: 763.doi:10.1186/s12885-016-2807-Y.
[7] Shires K, Xu LK, Rust A. Development of a multiplex assay to detect TERC and TERT mutations associated with immunosuppression therapy failure in Aplastic Anaemia patients[J]. Int J Lab Hematol, 2019, 41: e27-e31.
[8] Shallis RM, Ahmad R, Zeidan AM. Aplastic anemia: etiology, molecular pathogenesis, and emerging concepts[J]. Eur J Haematol, 2018, 101: 711-720.
[9] Wang C, Zhang T, Wang Y, et al. The shortening telomere length of T lymphocytes maybe associated with hyperfunction in servere aplastic anemia[J]. Mol Med Rep, 2018, 17: 1015-1021.
[10] Gadalla SM, Wang T, Dagnall C, et al. Effect of recipient age and stem cell source on the association between donor telomere length and survival after allogeneic unrelated hematopoietic cell transplantation for severe aplastic anemia[J]. Biol Blood Marrow Tr, 2016, 22: 2276-2282.
[11] Gadalla SM, Wang T, Haagenson M, et al. Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia[J]. JAMA, 2015, 313: 594-602.
[12] Townsley DM, Dumitriu B, Liu D, et al. Danazol treatment for telomere diseases[J]. New Engl J Med, 2016, 374: 1922-1931.
[13] Raval A, Behbehani GK, Thomas D, et al. Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout mice[J]. PLoS One, 2015, 10.doi:10.1371/journal.pone.0131722.
[14] Bar C, Povedano JM, Serrano R, et al. Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia[J]. Blood, 2016, 127: 1770-1779.
[15] Williams J, Heppel NH, Britt-Compton B, et al. Telo-mere length is an independent prognostic marker in MDS but not in de novo AML[J]. Brit J Haematol, 2017, 178: 240-249.
[16] Melguizo-Sanchis D, Xu Y, Taheem D, et al. iPSC modeling of severe aplastic anemia reveals impaired differentiation and telomere shortening in blood progenitors[J]. Cell Death Dis, 2018, 9: 128.doi:10.1038/s41419-017-0141-1.
[17] Colla S, Ong DST, Ogoti Y, et al. Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome[J]. Cancer Cell, 2015, 27: 644-657.
[18] Gadji M, Pozzo AR. From cellular morphology to molecular and epigenetic anomalies of myelodysplastic syndromes[J]. Gene Chromosome Canc, 2019, 58: 474-483.
[19] Shao Y, Qi X, Fu R, et al. Demonstration of IgG subclass (IgG1 and IgG3) in immuno-related hemocytopenia[J]. Clin Lab, 2018, 64: 1041-1048.
[20] Stoopler ET, Shanti RM. Dyskeratosis Congenita[C]. Mayo Clin Proc, 2019, 94: 1668-1669.
[21] Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Brit J Haematol, 2016, 172: 187-207.